S. Murray

Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study

J. Olié, E. Spina, Ruoyong Yang, 2006, International clinical psychopharmacology.

Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia.

P. Weiden, G. Simpson, T. Pigott, 2005, The American journal of psychiatry.

A Randomized, Placebo-Controlled Study Investigating the Nicotinic α7 Agonist, RG3487, for Cognitive Deficits in Schizophrenia

D. Umbricht, G. Garibaldi, R. Keefe, 2014, Neuropsychopharmacology.

Change in framingham risk score in patients with schizophrenia: a post hoc analysis of a randomized, double-blind, 6-week trial of ziprasidone and olanzapine.

B. Cuffel, D. Harrison, A. Loebel, 2006, Primary care companion to the Journal of clinical psychiatry.

P.2.046 Ziprasidone versus risperidone in schizophrenia: 52 weeks' comparative data

C. Pantelis, D. Addington, M. Dineen, 2003, European Neuropsychopharmacology.

P.2.085 Ziprasidone: Long-term post-switch efficacy in schizophrenia

P. Weiden, G. Simpson, A. Loebel, 2004, European Neuropsychopharmacology.